Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 5/20 | 0.61 |
| ▸ | HRH4 | Q9H3N8 | 10/20 | 0.60 |
| ▸ | NCF1 | P14598 | 1/20 | 0.58 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.56 |
| ▸ | HTR3B | O95264 | 1/20 | 0.56 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.56 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | GBA1 | P04062 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29124131 | 0.85 | NCF1 (0.50) | HTR3AHRH4NCF1KDM4EALDH1A1 | |
| SCHEMBL4262506 | 0.84 | NCF1 (0.56) | NCF1KDM4EALDH1A1LMNA | |
| SCHEMBL4770137 | 0.84 | SMN1; SMN2 (0.51) | HRH4ALDH1A1LMNAGBA1 | |
| SCHEMBL11275047 | 0.81 | NCF1 (0.58) | NCF1KDM4EALDH1A1LMNA | |
| SCHEMBL12215244 | 0.81 | HTR2C (0.59) | HTR3AHRH4NCF1HTR3EHTR3B | |
| SCHEMBL13169927 | 0.81 | HRH4 (0.59) | HTR3AHRH4NCF1HTR3EHTR3B | |
| Hydrochloric Acid SCHEMBL3688243 | 0.80 | HRH4 (0.57) | HTR3AHRH4NCF1HTR3EHTR3B | |
| SCHEMBL11282819 | 0.80 | ALDH1A1 (0.53) | HTR3AKDM4EALDH1A1LMNA | |
| SCHEMBL27945701 | 0.80 | HRH4 (0.64) | HTR3AHRH4NCF1HTR3EHTR3B | |
| SCHEMBL3623818 | 0.79 | KDM4E (0.55) | HTR3AHRH4HTR3EHTR3BHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222330-A1 | New Compounds | BIOVITRUM AB (SE) | 2010-09-02 | — | — | US | claimed |
| EP-1412325-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS, PROCESS FOR THEIR USE AS MEDICAMENT FOR THE TREATMENT OF CNS DISORDERS, OBESITY AND TYPE II DIABETES | BIOVITRUM AB (SE) | 2004-04-28 | — | — | EP | claimed |
| US-20030158202-A1 | Substituted fused ring sulfonamides containing, e.g., naphthalene, isoquinoline, quinoline, benzofuran or benzothiophene rings; treatment of conditions relating to obesity, type II diabetes and CNS disorders | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2003-08-21 | — | — | US | claimed |
| WO-2002100822-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS, PROCESS FOR THEIR USE AS MEDICAMENT FOR THE TREATMENT OF CNS DISORDERS, OBESITY AND TYPE II DIABETES | BIOVITRUM AB (SE) | 2002-12-19 | — | — | WO | claimed |
| EP-2386545-A1 | Heteroaryl ureas containing nitrogen hetero-atoms as P38 kinase inhibitors | Bayer Healthcare LLC (US) | 2011-11-16 | — | — | EP | disclosed |
| EP-1379507-B1 | HETEROARYL UREAS CONTAINING NITROGEN HETERO-ATOMS AS p38 KINASE INHIBITORS | BAYER HEALTHCARE LLC (US) | 2011-08-17 | — | — | EP | disclosed |
| US-7928239-B2 | Anticarcinogenic agents | BAYER HEALTHCARE LLC (US) | 2011-04-19 | — | — | US | disclosed |
| US-20100222330-A1 | New Compounds | BIOVITRUM AB (SE) | 2010-09-02 | — | — | US | disclosed |
| US-7572787-B2 | Substituted naphthalene sulfonamides | BIOVITRUM AB (SE) | 2009-08-11 | — | — | US | disclosed |
| US-20080194580-A1 | Inhibition Of Raf Kinase Using Quinolyl, Isoquinolyl Or Pyridyl Ureas | BAYER HEALTHCARE LLC | 2008-08-14 | — | — | US | disclosed |
| US-7371763-B2 | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-05-13 | — | — | US | disclosed |
| US-20070066600-A1 | Compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2007-03-22 | — | — | US | disclosed |
| US-20030207914-A1 | INHIBITION OF RAF KINASE USING QUINOLYL, ISOQUINOLYL OR PYRIDYL UREAS | BAYER CORPORATION | 2003-11-06 | — | — | US | disclosed |
| US-20030158202-A1 | Substituted fused ring sulfonamides containing, e.g., naphthalene, isoquinoline, quinoline, benzofuran or benzothiophene rings; treatment of conditions relating to obesity, type II diabetes and CNS disorders | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2003-08-21 | — | — | US | disclosed |
| WO-2002100822-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS, PROCESS FOR THEIR USE AS MEDICAMENT FOR THE TREATMENT OF CNS DISORDERS, OBESITY AND TYPE II DIABETES | BIOVITRUM AB (SE) | 2002-12-19 | — | — | WO | disclosed |
| US-20020165394-A1 | Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas | BAYER CORPORATION | 2002-11-07 | — | — | US | disclosed |
| WO-2002085859-A1 | HETEROARYL UREAS CONTAINING NITROGEN HETERO-ATOMS AS p38 KINASE INHIBITORS | BAYER CORPORATION (US) | 2002-10-31 | — | — | WO | disclosed |
| WO-2002085857-A2 | INHIBITION OF RAF KINASE USING QUINOLYL, ISOQUINOLYL OR PYRIDYL UREAS | BAYER CORPORATION (US) | 2002-10-31 | — | — | WO | disclosed |
| WO-2002062763-A2 | INHIBITION OF RAF KINASE USING QUINOLYL ISOQUINOLYL OR PYRIDYL UREAS | BAYER CORPORATION (US) | 2002-08-15 | — | — | WO | disclosed |
| US-20020065296-A1 | Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors | BAYER CORPORATION | 2002-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165394-A1 | Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas | BRAF, RAF1, ARAF | HTR3A 4237/4885HRH4 1344/4885NCF1 1988/4885 |
| US-20030158202-A1 | Substituted fused ring sulfonamides containing, e.g., naphthalene, isoquinoline, quinoline, benzofuran or benzothiophene rings; treatment of conditions relating to obesity, type II diabetes and CNS disorders | SULT2A1, SULT1A1, SULT1E1 | HTR3A 3042/4885HRH4 855/4885NCF1 1239/4885 |
| US-20080194580-A1 | Inhibition Of Raf Kinase Using Quinolyl, Isoquinolyl Or Pyridyl Ureas | BRAF, RAF1, ARAF | HTR3A 4254/4885HRH4 1639/4885NCF1 2295/4885 |
| US-20070066600-A1 | Compounds | SULT2A1, STS, SLC5A2 | HTR3A 2991/4885HRH4 1960/4885NCF1 2806/4885 |
| US-20030207914-A1 | INHIBITION OF RAF KINASE USING QUINOLYL, ISOQUINOLYL OR PYRIDYL UREAS | BRAF, RAF1, ARAF | HTR3A 4254/4885HRH4 1639/4885NCF1 2295/4885 |
| US-20020065296-A1 | Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors | MAPK1, MAP3K1, MAPK3 | HTR3A 2012/4885HRH4 1648/4885NCF1 493/4885 |
| US-20100222330-A1 | New Compounds | SULT2A1, GPR119, STS | HTR3A 3223/4885HRH4 2191/4885NCF1 2967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.